Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1000 participants.
Also called NCT06577519
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,000 participants
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Registry
-
NCT06577519
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT06577519. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-06 (actual); primary completion 2026-12-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
- Condition
- Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI (percutaneous coronary intervention))
- Intervention (Drug)
- Vicagrel
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Record details
- Record id
cardio:ct-nct06577519- Content hash
6f0203bfdc6bfffe76a0e896f9db809150faaccbaff89477e0a00bf7bda4a0ce